Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Mitochondrial electron transport chain and parasite transport proteins represent a broad category of essential physiological systems in protozoan parasites, most notably Plasmodium species (Painter et al., 2007, Nature). The mitochondrial electron transport chain (mETC) is vital for parasite survival, primarily because it serves as a sink for electrons generated during de novo pyrimidine biosynthesis via dihydroorotate dehydrogenase, rather than solely for ATP production (Painter et al., 2007, Nature). Parasite transport proteins, including the Chloroquine Resistance Transporter (PfCRT) and various ion-motive ATPases like PfATP4, are responsible for maintaining electrochemical gradients, nutrient uptake, and the efflux of metabolic waste or drugs (Fidock et al., 2000, Molecular Cell; Rottmann et al., 2010, Science). Drugs such as atovaquone target the cytochrome bc1 complex (Complex III) of the mETC, disrupting the membrane potential and halting pyrimidine synthesis (Birth et al., 2014, Nature Communications). Meanwhile, drugs like cipargamin target PfATP4 to disrupt sodium homeostasis, leading to parasite lysis (Vaidya et al., 2014, Nature Communications). This target group is a cornerstone of antimalarial therapy, though its utility is constantly challenged by the emergence of point mutations that confer high-level drug resistance (Haldar et al., 2018, Nature Reviews Microbiology).
Inhibition of the cytochrome bc1 complex (Complex III) to disrupt mitochondrial membrane potential and pyrimidine biosynthesis; inhibition of P-type ATPases (e.g., PfATP4) to disrupt ion homeostasis; modulation of vacuolar transporters to alter drug accumulation (Painter et al., 2007, Nature; Rottmann et al., 2010, Science).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial electron transport chain and parasite transport proteins (mETC/PTPs).